These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 12871417

  • 1. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
    Aubert H, Frère C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC.
    J Thromb Haemost; 2003 Apr; 1(4):791-7. PubMed ID: 12871417
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 3. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 4. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 5. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.
    J Clin Endocrinol Metab; 2002 Feb; 87(2):660-5. PubMed ID: 11836301
    [Abstract] [Full Text] [Related]

  • 6. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [Abstract] [Full Text] [Related]

  • 7. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 8. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 08; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 08; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC.
    Arterioscler Thromb Vasc Biol; 2000 Sep 08; 20(9):2156-61. PubMed ID: 10978263
    [Abstract] [Full Text] [Related]

  • 11. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 08; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 12. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 13. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 14. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Jun 06; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 15. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 06; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 16. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
    De Pergola G, De Mitrio V, Sciaraffia M, Pannacciulli N, Minenna A, Giorgino F, Petronelli M, Laudadio E, Giorgino R.
    Metabolism; 1997 Nov 06; 46(11):1287-93. PubMed ID: 9361687
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
    Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Haemost; 2003 Dec 06; 90(6):1187-91. PubMed ID: 14652655
    [Abstract] [Full Text] [Related]

  • 18. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun 06; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

  • 19. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.
    J Thromb Haemost; 2013 Feb 06; 11(2):315-24. PubMed ID: 23256818
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 06; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.